German-based contract manufacturer apceth has received regulatory approval to use two new GMP cleanrooms for aseptic processing, which will be used for the handling and genetic manipulation of various types of cell and gene therapies.
Rumoured Big Pharma takeover target GSK has invested $95m to set up an cell genetics research institute to help developers better identify drug candidates.
Aragen Bioscience and Transposagen Biopharmaceuticals have launched a knockout CHO cell line and development services they clam allows for the development of more effective therapeutic mAbs.
As the largest pharma and tech suppliers – from Novartis to GE Healthcare to Thermo Fisher – begin exploring the world of CRISPR/Cas gene editing technology, contract research organizations are also looking into the new tech to explore ways to help clients’...
A drug candidate which prevents the export of viral RNA in infected cells could lead the way in developing a functional cure for HIV, according to Abivax.
Gene-editing technology CRISPR-Cas9 must not be used to alter human DNA until the risks have been researched and the ethical issues considered, say scientists.
Chinese cancer drug developer BeiGene will create production cell lines using a platform developed by Sigma Aldrich's custom manufacturing services business.
China-based CDMO WuXi PharmaTech unveiled Thursday that it will soon begin construction on its third cell therapy manufacturing facility -- a 145,000-square-foot cGMP facility in Philadelphia.
AstraZeneca has partnered to use the CRISPR genome editing technique across its discovery programmes in a move that puts it on a collision course with French Biotech, Cellectis.
PPD’s recently acquired biotech company X-Chem is launching a multi-target collaboration with Janssen Biotech. Financial terms of the deal were not disclosed.
Horizon says its £6m (€7.7m) purchase of Austrian biotech Haplogen Genomics means it can produce cell lines ten times faster than before using a haploid gene platform.
Isis Pharmaceuticals and AstraZeneca have expanded their partnership to develop novel delivery methods for antisense oligonucleotides in order to target the desired tissue more effectively.
Protalix shares rocketed 18% then reversed in one weekend after the Israeli protein manufacturer clarified it is not in talks to produce Ebola drug ZMapp.
AMRI has added protein expression and purification services to its drug discovery services citing the shift in pipelines towards larger molecule drugs as a driver.
Horizon Discovery says the gene editing tool CRISPR used to engineer its human cell lines is exploding the possibilities of screening for preclinical customers.
WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services for clinical research, has acquired biosafety consultancy Alliance Biosciences. Financial terms of the deal were not disclosed.
The complex nature of biopharmaceuticals dictates the choice of contract manufacturer when compared with selecting a partner for small molecule drugs, according to a life sciences consultant.
The European Medicines Agency’s Committee for Advanced Therapies (CAT) has revised a reflection paper on the classification of advanced-therapy medicinal products (ATMPs) to reflect cases in which medicines can be classified as ATMPs.
French mAb developers that hire Cobra Biologics stand to benefit from tax breaks after the French Ministry of Higher Education and Research (MESR) named the CMO as a preferred provider.
WuXi PharmaTech is partnering with Pacific Biomarkers to gain access to its menu of validated biomarker assays to support WuXi's integrated clinical trial testing services.
Cobra Biologics is looking for more scientists with plasmid production skills after BioCancell became the fifth firm in a year to ask the CMO to manufacture a DNA-based gene therapy candidate.
Bioreliance has launched an updated version of its mutagenicity service after conducting studies that confirmed its Big Blue Mouse assay still meets OECD standards.
With the Chinese NAP (nucleic acid purification) market expected to grow more than 8% over the next year and no clear market leaders, companies are looking to take control of the industry space.
Integrated DNA Technologies (IDT) has opened a facility in Singapore in order to manufacture oligonucleotides for research companies throughout the region.
The US Supreme Court has ruled unanimously that naturally occurring DNA is not patentable “merely because it has been isolated,” but synthetic DNA can be patented.
As Cobra wins a cell line development contract with Recopharma, the firm says its cost-effective gene expression technology has been its biggest growth area.
Cobra Biologics is confident it can win the commercial contract for Vaccibody AS’ candidate DNA vaccine, citing its production platform and recent capacity expansion as key.
Food industry controls do not ensure porcine trypsin is virus-free according to the EMA, which proposes testing procedures for drugmakers which use the reagent in a new consultation document.
Thermo Fisher Scientific has set up a unit for molecular biology techs at its site in Lithuania, citing pharmaceutical R&D labs in Eastern Europe as a target.
Genomic analysis seems to be an area of interest for the contract services sector at the moment with Northern Ireland-based Almac and US CRO Quintiles only the latest firms to make investments in the field.
